Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

<ul>
<li>Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.</li>
<li>We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.</li>
<li>We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.</li>
</ul>


Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.
We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.
We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.


Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Infervision Medical Technology / Equity Capital Markets

<p>This year, many AI startups are preparing IPO, among which AI medical companies are one of the main forces. For example, after <a href="https://www.smartkarma.com/entities/beijing-airdoc-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33524:1" rel="noopener">Beijing Airdoc Technology (BAT HK)</a><a href="https://www.smartkarma.com/entities/beijing-keya-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:32228:1" rel="noopener">,</a> another company in this field <a href="https://www.smartkarma.com/entities/infervision-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:34296:1" rel="noopener">Infervision Medical Technology (IMT HK)</a> also submitted its prospectus to the HKEX and officially started its IPO process. Infervision is an AI medical technology company dedicated to the R&amp;D and commercialization of AI medical products that precisely address the industry pain points. This article mainly analyzed the industry characteristics, the business and the concerns of the Company. </p>

This year, many AI startups are preparing IPO, among which AI medical companies are one of the main forces. For example, after Beijing Airdoc Technology (BAT HK), another company in this field Infervision Medical Technology (IMT HK) also submitted its prospectus to the HKEX and officially started its IPO process. Infervision is an AI medical technology company dedicated to the R&amp;D and commercialization of AI medical products that precisely address the industry pain points. This article mainly analyzed the industry characteristics, the business and the concerns of the Company. 

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

Beijing Keya Medical Technology / Equity Capital Markets

<p>The combination of AI and medical treatment has become a major development trend in the future medical field. In this context, many participants in the AI medical market have more desire for the public capital markets. For example, on March 16, 2021, <a href="https://www.smartkarma.com/entities/beijing-keya-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:32228:1" rel="noopener">Beijing Keya Medical Technology (BKM CH)</a>, an artificial intelligence (AI) medical device company, submitted an application to the Hong Kong Stock Exchange to be listed on the main board. Keya, founded in 2016, is quite favored by capital. Up to now, Keya has completed six rounds of financing. Especially in 2020, it completed four rounds of financing with the amount of nearly RMB900 million. The following mainly analyzed both the strength and the concerns of the Company.</p>

The combination of AI and medical treatment has become a major development trend in the future medical field. In this context, many participants in the AI medical market have more desire for the public capital markets. For example, on March 16, 2021, Beijing Keya Medical Technology (BKM CH), an artificial intelligence (AI) medical device company, submitted an application to the Hong Kong Stock Exchange to be listed on the main board. Keya, founded in 2016, is quite favored by capital. Up to now, Keya has completed six rounds of financing. Especially in 2020, it completed four rounds of financing with the amount of nearly RMB900 million. The following mainly analyzed both the strength and the concerns of the Company.

Pre-IPO Beijing Keya Medical Technology - Here Are the Strength and the Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Beijing Keya Medical Technology (BKM CH)

Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

Shanghai Pulse Medical is a leading player in the FFR assessment in China. We look at the product line of the company, including QFR, OFR and UFR.

Ke Yan, CFA, FRM

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

This article mainly analyzed Infervision Medical Technology in terms of the AI medical industry characteristics, the business, the product layout,...

Xinyao (Criss) Wang

Pre-IPO Beijing Keya Medical Technology - Here Are the Strength and the Concerns

The article analyzed Keya Medical Technology in terms of industry characteristics, related policy, financial position and concerns such as safety...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)